Literature DB >> 10065120

Mortality associated with New South Wales methadone programs in 1994: lives lost and saved.

J R Caplehorn1, O H Drummer.   

Abstract

OBJECTIVES: To estimate the effects of methadone programs in New South Wales on mortality. DESIGN AND CASES: Retrospective, cross-sectional study of all 1994 New South Wales coronial cases in which methadone was detected in postmortem specimens taken from the deceased. Cases were people we identified as patients in NSW methadone maintenance programs or those whose deaths involved methadone syrup diverted from maintenance programs. OUTCOME MEASURES: Relative risks of fatal, accidental drug toxicity in the first two weeks of treatment and later; the number of lives lost as a result of maintenance treatment; preadmission risks and the number of lives saved by maintenance programs, calculated from data from a previous study.
RESULTS: There was very close agreement between this study's classifications and official pathology reports of accidental drug toxicity. The relative risk (RR) of fatal accidental drug toxicity for patients in the first two weeks of methadone maintenance was 6.7 times that of heroin addicts not in treatment (95% CI RR, 3.3-13.9) and 97.8 times that of patients who had been in maintenance more than two weeks (95% CI RR, 36.7-260.5). Despite 10 people dying from iatrogenic methadone toxicity and diverted methadone syrup being involved in 26 fatalities. In 1994, NSW maintenance programs are estimated to have saved 68 lives (adjusted 95% CI, 29-128).
CONCLUSIONS: In 1994, untoward events associated with NSW methadone programs cost 36 lives in NSW. To reduce this mortality, doctors should carefully assess and closely monitor patients being admitted to methadone maintenance and limit the use of takeaway doses of methadone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065120     DOI: 10.5694/j.1326-5377.1999.tb127675.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  20 in total

1.  Toxicology and pathology of deaths related to methadone: retrospective review.

Authors:  S B Karch; B G Stephens
Journal:  West J Med       Date:  2000-01

2.  Is methadone a miracle cure or an alternative evil?

Authors:  R S Hoffman
Journal:  West J Med       Date:  2000-01

3.  Positive airway pressure treatment for opioid-related central sleep apnea, where are we now?

Authors:  David Wang; Luke Rowsell; Brendon J Yee
Journal:  Sleep Breath       Date:  2013-10-26       Impact factor: 2.816

Review 4.  A risk-benefit analysis of methadone maintenance treatment.

Authors:  J Bell; D Zador
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

Review 5.  Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

6.  Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.

Authors:  Hartmut Stocker; Guido Kruse; Peter Kreckel; Christian Herzmann; Keikawus Arastéh; Jörg Claus; Heiko Jessen; Christiane Cordes; Bettina Hintsche; Frank Schlote; Lothar Schneider; Michael Kurowski
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  Non-fatal overdose and subsequent drug treatment among injection drug users.

Authors:  Robin A Pollini; Lisa McCall; Shruti H Mehta; David Vlahov; Steffanie A Strathdee
Journal:  Drug Alcohol Depend       Date:  2005-11-23       Impact factor: 4.492

8.  Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.

Authors:  Kirsten E Smith; Martha D Tillson; Michele Staton; Erin M Winston
Journal:  Drug Alcohol Depend       Date:  2020-01-09       Impact factor: 4.492

Review 9.  Sleep-disordered breathing and psychiatric disorders.

Authors:  Haider A Naqvi; David Wang; Nicholas Glozier; Ronald R Grunstein
Journal:  Curr Psychiatry Rep       Date:  2014-12       Impact factor: 5.285

Review 10. 

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.